Amphastar Pharmaceuticals (NASDAQ:AMPH) Upgraded at Zacks Research

Zacks Research upgraded shares of Amphastar Pharmaceuticals (NASDAQ:AMPH) from a hold rating to a strong-buy rating in a research report released on Thursday,Zacks.com reports.

Several other research analysts also recently issued reports on AMPH. Needham & Company LLC raised shares of Amphastar Pharmaceuticals from a “hold” rating to a “buy” rating and set a $36.00 price objective on the stock in a research report on Tuesday, August 12th. Weiss Ratings reiterated a “hold (c-)” rating on shares of Amphastar Pharmaceuticals in a research note on Wednesday, October 8th. Bank of America boosted their price target on Amphastar Pharmaceuticals from $28.00 to $32.00 and gave the company a “neutral” rating in a research report on Tuesday, August 26th. Finally, Piper Sandler reduced their price objective on Amphastar Pharmaceuticals from $30.00 to $25.00 and set a “neutral” rating for the company in a research note on Friday, August 8th. One equities research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and four have issued a Hold rating to the company’s stock. According to data from MarketBeat, Amphastar Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus price target of $31.60.

Amphastar Pharmaceuticals Stock Performance

Shares of AMPH opened at $23.78 on Thursday. The company’s 50 day simple moving average is $27.86 and its 200-day simple moving average is $25.25. The firm has a market cap of $1.11 billion, a PE ratio of 8.91 and a beta of 0.75. Amphastar Pharmaceuticals has a 12-month low of $20.39 and a 12-month high of $53.96. The company has a current ratio of 3.29, a quick ratio of 2.21 and a debt-to-equity ratio of 0.80.

Hedge Funds Weigh In On Amphastar Pharmaceuticals

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Signaturefd LLC boosted its holdings in Amphastar Pharmaceuticals by 147.7% during the first quarter. Signaturefd LLC now owns 872 shares of the company’s stock worth $25,000 after buying an additional 520 shares in the last quarter. Farther Finance Advisors LLC lifted its position in shares of Amphastar Pharmaceuticals by 356.0% during the 3rd quarter. Farther Finance Advisors LLC now owns 944 shares of the company’s stock valued at $25,000 after acquiring an additional 737 shares during the period. MassMutual Private Wealth & Trust FSB lifted its position in shares of Amphastar Pharmaceuticals by 192.8% during the 2nd quarter. MassMutual Private Wealth & Trust FSB now owns 1,262 shares of the company’s stock valued at $29,000 after acquiring an additional 831 shares during the period. Hantz Financial Services Inc. boosted its stake in shares of Amphastar Pharmaceuticals by 3,430.8% during the 2nd quarter. Hantz Financial Services Inc. now owns 1,377 shares of the company’s stock worth $32,000 after acquiring an additional 1,338 shares in the last quarter. Finally, IFP Advisors Inc acquired a new stake in shares of Amphastar Pharmaceuticals in the 1st quarter worth approximately $34,000. 65.09% of the stock is owned by institutional investors and hedge funds.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.